Direkt zum Inhalt
Merck

Platelet factor 4 regulation of monocyte KLF4 in experimental cerebral malaria.

PloS one (2010-05-11)
Kalyan Srivastava, David J Field, Angela Aggrey, Munekazu Yamakuchi, Craig N Morrell
ZUSAMMENFASSUNG

Cerebral malaria continues to be a difficult to treat complication of Plasmodium falciparum infection in children. We have shown that platelets can have major deleterious immune functions in experimental cerebral malaria (ECM). One of the platelet derived mediators we have identified as particularly important is platelet factor 4/CXCL4. Our prior work demonstrated that PF4(-/-) mice are protected from ECM, have reduced plasma cytokines, and have reduced T-cell trafficking to the brain. We now show that PF4 drives monocyte cytokine production in a Kruppel like factor 4 (KLF4) dependent manner. Monocyte depleted Plasmodium berghei infected mice have improved survival, and KLF4 is greatly increased in control, but not monocyte depleted mice. PF4(-/-) mice have less cerebral monocyte trafficking and no change in KLF4 expression. These data indicate that PF4 induction of monocyte KLF4 expression may be an important step in the pathogenesis of ECM.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
PF-4 from mouse, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture